Gaurav Chatterjee
Overview
Explore the profile of Gaurav Chatterjee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
285
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gokarn A, Reddy L, Hiregoudar S, Poojary M, Parab S, Punatar S, et al.
Cytotherapy
. 2025 Feb;
PMID: 39903142
Background: Various chemotherapy regimens have been used for chemo-mobilization of stem cells prior to autologous stem cell transplant in patients with Hodgkin lymphoma, and there is no clear standard of...
2.
Roy Moulik N, Keerthivasagam S, Chatterjee G, Agiwale J, Rane P, Dhamne C, et al.
Am J Hematol
. 2024 Nov;
100(2):210-217.
PMID: 39568222
Pediatric chronic myeloid leukemia (pCML) is a rare childhood malignancy, representing 2%-3% of all childhood leukemia. Tyrosine kinase inhibitors (TKIs) have greatly improved survival but pose challenges due to their...
3.
Sarma R, Kashyap L, Srikanth A, Mondal T, Kashyap Y, Nandhana R, et al.
Indian J Hematol Blood Transfus
. 2024 Oct;
40(4):564-572.
PMID: 39469157
Chronic myeloid leukaemia (CML) is caused by balanced translocation t(9::22)(q34;q11) resulting in formation of pathogenic BCR-ABL fusion gene. Tyrosine kinase inhibitors (TKI) have revolutionised the treatment of CML. Ongoing treatment...
4.
Chatterjee G, He R, Patkar N, Viswanatha D, Langerak A
Histopathology
. 2024 Oct;
86(1):38-57.
PMID: 39403025
Here we review the 'what and how' of molecular techniques used in the context of haematopathological diagnostics of both lymphoid and myeloid neoplasms. Keeping in mind that the required resources...
5.
Singh A, Patil J, Ghogale S, Deshpande N, Girase K, Shetye N, et al.
Cytometry B Clin Cytom
. 2024 Jul;
106(5):359-369.
PMID: 39031805
Multicolor flow cytometry (MFC) is crucial in detecting occult or minimal bone marrow (BM) involvement by non-Hodgkin lymphomas (NHL), which may not be detected using trephine biopsy or imaging studies....
6.
Kamtalwar S, Mirgh S, More A, Sharma P, Patkar N, Rajpal S, et al.
South Asian J Cancer
. 2024 Jun;
13(2):157-162.
PMID: 38919664
No abstract available.
7.
Tembhare P, Sriram H, Khanka T, Gawai S, Bagal B, Ghogale S, et al.
Hemasphere
. 2024 Apr;
8(4):e63.
PMID: 38566804
Circulating tumor plasma cells (CTPCs) provide a noninvasive alternative for measuring tumor burden in newly diagnosed multiple myeloma (NDMM). Moreover, measurable residual disease (MRD) assessment in peripheral blood (PBMRD) can...
8.
Roy Moulik N, Keerthivasagam S, Pandey A, Agiwale J, Hegde K, Chatterjee G, et al.
Br J Haematol
. 2023 Dec;
204(4):1249-1261.
PMID: 38098201
Tyrosine kinase inhibitors (TKIs) have drastically improved the outcomes of pCML (paediatric CML) but data on long-term off-target toxicities of TKIs in children are scarce. In this single-centre, retrospective cum...
9.
Srinivasan S, Dhamne C, Patkar N, Chatterjee G, Roy Moulik N, Chichra A, et al.
Pediatr Blood Cancer
. 2023 Nov;
71(2):e30791.
PMID: 38014874
Background: Pediatric core binding factor acute myeloid leukemia (CBF-AML), although considered a favorable risk subtype, exhibits variable outcomes primarily driven by additional genetic abnormalities, such as KIT mutations. Procedure: In...
10.
Chatterjee G, Dhende P, Raj S, Shetty V, Ghogale S, Deshpande N, et al.
Eur J Haematol
. 2023 Sep;
112(1):122-136.
PMID: 37706583
Objectives: Measurable residual disease (MRD) is the most relevant predictor of disease-free survival in B-cell acute lymphoblastic leukemia (B-ALL). We aimed to establish a highly sensitive flow cytometry (MFC)-based B-ALL-MRD...